Picture of Allergy Therapeutics logo

AGY — Allergy Therapeutics Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapFalling Star

Momentum

Relative Strength (%)
1m-6.03%
3m-14.51%
6m-32.3%
1yr-19.52%
Volume Change (%)
10d/3m-59.96%
Price vs... (%)
52w High-51.85%
50d MA-10.99%
200d MA-30.88%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value2.28
Price to Tang. Book2.47
Price to Free Cashflown/a
Price to Sales1.59
EV to EBITDA560.27

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-5.75%
Return on Equity-9.47%
Operating Margin-5.48%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for AGY

Allergy Therapeutics (LON:AGY): buy, sell or hold? background image

Allergy Therapeutics (LON:AGY): buy, sell or hold?

Shares in Allergy Therapeutics (LON:AGY) are currently trading close to a 52 week high, with the share price up by around 7.25% - to 35.5p - over the past week. On a one-month basis, the Allergy Therapeutics share price has risen by 20...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202230th Jun 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Allergy Therapeutics EPS forecast chart

Profile Summary

Allergy Therapeutics plc is a United Kingdom-based commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines. Its segments include Central Europe, which include segments, such as Germany, Austria, Switzerland and the Netherlands; Southern Europe, which includes Italy, Spain and Other; the United Kingdom, and Rest of World. It sells both injectable and sublingual allergen-specific immunotherapies. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL and Peanut SCIT. Its vaccine candidates outside allergy include disease areas, including cancer, asthma, atopic dermatitis and psoriasis. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Venomil, VLP Peanut and ImmunoBON.

Directors

Last Annual
June 30th, 2021
Last Interim
December 31st, 2021
Incorporated
June 1st, 2004
Public Since
October 11th, 2004
No. of Employees
601
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
gb flag iconLondon Stock Exchange
Shares in Issue
643,998,996

AGY Share Price Performance

Similar to AGY

Picture of 4Basebio logo

4Basebio

gb flag iconLondon Stock Exchange

Picture of 4d Pharma logo

4d Pharma

gb flag iconLondon Stock Exchange

Picture of Arecor Therapeutics logo

Arecor Therapeutics

gb flag iconLondon Stock Exchange

Picture of Avacta logo

Avacta

gb flag iconLondon Stock Exchange

Picture of Bioventix logo

Bioventix

gb flag iconLondon Stock Exchange

FAQ

Or unlock with your email

Or unlock with your email